7 results
Antiplatelet Conversion - Switching Between P2Y12 Inhibitors
Oral P2Y12 inhibitors vary in potency and pharmacokinetic and dynamic
Antiplatelet Conversion - Switching ... Switching P2Y12 ... • Switching Between ... to Ticagrelor, ... Ticagrelor to Prasugrel
Antiplatelet Conversion - P2Y12 Inhibitor Switching
 • Clopidogrel (Plavix)
 • Prasugrel (Effient)
 • Ticagrelor (Brilinta)
Clopidogrel and
Antiplatelet Conversion - P2Y12 ... Inhibitor Switching ... (Effient) • Ticagrelor ... active site of the P2Y12 ... #Inhibitor #Switching
Antiplatelet Conversion - Switching Between Oral P2Y12 Inhibitors
A, Switching between oral agents in the acute/early phase.
Between Oral P2Y12 ... escalating to prasugrel ... hours after last prasugrel ... to prasugrel therapy ... CIRCULATIONAHA.117.031164 #P2Y12
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous
Adenosine Diphosphate P2Y12 ... Inhibitor Use and Adherence ... EBM #Cardiology #Adherence ... #Clopidogrel #Prasugrel ... #Ticagrelor #Plavix
Oral P2Y12 Inhibitor Pharmacology

 • Clopidogrel
 • Prasugrel
 • Ticagrelor

By Kyle Fischer, PharmD @Kfischer_10

#P2Y12 #Inhibitor #Pharmacology
Oral P2Y12 Inhibitor ... Clopidogrel • Prasugrel ... • Ticagrelor ... Kfischer_10 #P2Y12
Antiplatelet Medications - Summary Table

Aspirin - Inhibits cyclooxygenase, preventing formation of thromboxane A2
 • Acute coronary
combination with P2Y12 ... anticoagulation in a-fib P2Y12 ... (clopidogrel, prasugrel ... , ticagrelor) - ... Inhibits the P2Y12
Cangrelor - Pharmacology
Cangrelor (Kengreal) is a parenteral analogue of adenosine triphosphate
Cangrelor binds reversibly to the platelet
to the platelet P2Y12 ... Antiplatelet: • Both prasugrel ... clopidogrel and prasugrel ... subtherapeutic levels • Ticagrelor ... Ticagrelor's half-life